OMA Logo

June 3, 2024

Pediatric Research Update | Treatment of Hypothalamic Obesity

Share this post

Og image oma

Each month, the OMA Pediatric Committee reviews a pediatric-focused obesity research update to help keep you up to date about the latest findings. This month’s update addresses treatment of hypothalamic obesity.

Treatment of Hypothalamic Obesity in People with Hypothalamic Injury: New Drugs are on the Horizon

Article Summary

Hypothalamic obesity (HO) is a complex disorder resulting from either monogenic cause or injury of the hypothalamus. Lifestyle intervention alone is usually ineffective. This article aims to discuss newer treatments for HO.

Read Full Article

Article Review

The article addresses the complex condition of hypothalamic obesity (HO). It briefly discusses the two types of HO which are genetic or acquired. The authors primarily concentrate on acquired HO, which arises from hypothalamic lesion often treated through surgery and/ or radiation. Craniopharyngioma (CP) is identified as the most prevalent cause of acquired HO.

In discussing the pathophysiology and phenotypes of acquired HO, the authors describe a syndrome characterized by excessive weight gain resulting from hyperphagia potentially due to leptin resistance and deficiencies in downstream energy regulation neuroendocrine pathway. Additional features include decreased sympathetic activity, low energy expenditure, temperature dysregulation, and increased energy storage in adipose tissue, all of which are very similar in patients with monogenic cause of HO.

The article highlights the lack of FDA approved treatment specifically for HO but reviews existing medications currently approved for general obesity such as GLP-1 receptor agonists (GLP1Ras) and combination Phentermine/ Topiramate. It also mentions drugs that had undergone clinical trials for HO including oxytocin and Tesofensine. Currently, Setmelanotide, a MC4R agonist approved for certain monogenic obesity forms is undergoing clinical trials for acquired HO.

As obesity pharmacotherapy is rapidly evolving, the development of newer drugs is anticipated. Tirzepitide, approved for adult Type 2 diabetes, has demonstrated 20% weight loss, while Retatrutide, a triple agonist (GIP, GLP and glucagon) is currently in a phase 2 clinical trial showing 24.2% weight loss over 48 weeks.

Treatment for HO should be tailored based on phenotype spectrum as previously discussed, recommending a switch to another drug or combination therapy if there is no response after three months.

As a final statement, authors propose that MC4R agonism could represent a new standard of treatment for HO.

Table of Contents

Get the latest news about OMA’s live educational events and online courses.

Subscribe

Roth CL, Zenno A. Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon. Front Endocrinol (Lausanne). 2023 Sep 13;14:1256514. doi: 10.3389/fendo.2023.1256514. PMID: 37780616; PMCID: PMC10533996.

Article reviewed by:

Chan Headshot

Jacqueline T. Chan, MD, FAAP, DABOM

Dr. Jacqueline Chan completed her Pediatric residency at Sinai Children's Hospital, and her Pediatric endocrinology Fellowship at University Of Illinois Chicago/ Rush University. 

Dr. Chan is certified in Pediatrics, Pediatric Endocrinology and Obesity Medicine. She was an assistant professor of pediatrics faculty at the Children’s hospital of Georgia for 5 years. She has provided multiple education lecture series and podcasts about various endocrine and metabolic issues. In addition, she has published multiple peer reviewed articles and is an active member of the Obesity Medicine Association Pediatric Committee.

Dr. Chan is currently an Assistant Professor of Pediatrics at the University of Utah and is in the Division of Pediatric Endocrinology at Primary Children´s Medical Center where Dr. Chan and is leading a multidisciplinary team for children with obesity. Her interest is on comorbidities associated with pediatric obesity mainly Type 2 diabetes and lipid disorders, as well as Hypothalamic obesity.

Home visit by family doctor providing medical care and advice in a family home setting.
08/27/26

Pediatric Research Update: Growing Under Pressure: Obesity and Children’s Musculoskeletal Health

Article Summary Physical activity is a fundamental pillar of a healthy lifestyle and an essential part of effective weight management for children and adolescents, supporting healthy growth, physical and mental well-being, and prevention of excessive weight gain during critical developmental years. The article, "Consequences of Overweight and Obesity on the Musculoskeletal System in Children: A Review of Recent Literature," examines how excess body weight stresses developing bones, joints, muscles, and connective tissues, potentially leading to orthopedic and functional complications that can persist into adulthood. By synthesizing current evidence, the review offers valuable insight for clinical practice, targeted intervention, and future research aimed at improving long-term musculoskeletal health in children and adolescents. (2025), "Consequences of overweight and obesity on the musculoskeletal system in children: a review of recent literature," lays out why: adiposity places real, measurable strain on the growing skeleton, in ways that go well beyond simple wear and tear. Physical activity is one of the core pillars of comprehensive obesity care, and current guidelines recommend 60 minutes of daily activity for children and adolescents. Clinically, ask about joint pain, exercise intolerance, and gait changes as part of routine obesity visits, and incorporate a basic assessment of movement and mobility rather than waiting for a child to volunteer that something hurts. A thorough visit should assess mobility, functional status, and quality of life, and screen for psychosocial barriers to activity, with referrals to physical therapy, exercise physiology, or behavioral health as needed2 Consider adding standardized quality-of-life or functional-status measures to routine obesity visits, and expanding access to behavioral health support alongside physical activity resources. Routine visits should include balance, gait, and fall-history assessment, with physical therapy referral for children showing gait abnormalities or recurrent injury. Conclusion The musculoskeletal effects of pediatric obesity are complex and can affect mobility, physical activity, and quality of life. Treating the whole child means making musculoskeletal health part of routine obesity care. Consequences of overweight and obesity on the musculoskeletal system in children: a review of recent literature.

Continue reading
Adobe Stock 1123180511
06/23/26

Pediatric Research Update: The New Name for PCOS - Now PMOS

An international steering group conducted a rigorous global consensus process for renaming polycystic ovary syndrome, leading to a consensus regarding the terminology change

Continue reading
Og image oma
05/17/26

Pediatric Research Update: Physical Activity Patterns and Associations in Infants and Toddlers

The most increase in physical activity (PA) was found to be from infancy to 24 months and then tended to plateau. Greater screen time exposure was associated with a slower rate of PA increase between 6 and 24 months of age. Based on these findings, clinicians should consider integrating PA anticipatory guidance into well-child visits beginning in early infancy, with attention to screen time limits and opportunities for active play. In their original article, Longitudinal Change in Physical Activity in Children 6 to 36 Months of Age , Pate and colleagues not only present the developmental pattern for PA in this age group but also highlight factors that may hinder or promote PA development. Interestingly, screen time was associated with higher PA levels at 6 months but with a slower rate of PA growth by 24 months, suggesting that the negative impact of screen exposure on physical activity accumulates over time rather than appearing immediately. Longitudinal Change in Physical Activity in Children 6 to 36 Months of Age.

Continue reading